Journal
VACCINE
Volume 40, Issue 5, Pages 819-825Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2021.12.028
Keywords
Tick-borne encephalitis; TBE; Vaccine effectiveness; FSME-IMMUN; Vaccination schedule; Age groups
Categories
Funding
- Pfizer Inc.
Ask authors/readers for more resources
The study found that the VE after 2, 3, and >4 doses of TBE vaccine was high in both Latvia and southern Germany, with little difference regardless of age groups within or outside the vaccination schedule. The results suggest that longer and more flexible booster intervals may be considered for sustainable long-term protection.
Background: Tick-borne encephalitis (TBE) is a vaccine-preventable disease which may cause long-term sequelae and even death. The data on the long-term effectiveness of TBE vaccines are limited. Additionally, the vaccination schedule is complex which in part contributes towards sub-optimal uptake in TBE-endemic areas. The current ecological study measures vaccine effectiveness (VE) in two European countries. Methods: TBE VE was measured from 2007 to 2018 in Latvia and Southern German states by age group, vaccination history, and schedule compliance. TBE cases and vaccination history were obtained from the public health agencies for Latvia and the southern German federal states of Bavaria and BadenWuerttemberg. Cases were within schedule if a TBE infection was diagnosed within the time interval preceding the next scheduled dose and outside schedule if the diagnosis occurred after the next scheduled dose. Vaccine uptake was estimated via representative nationwide surveys. Results: VE after 2, 3, and >4 doses was high in both countries at 97.2%, 95.0%, and 95.4% for southern Germany, and 98.1%, 99.4%, and 98.8% for Latvia while within- schedule, and only showed marginal differences outside schedule at 90.6%, 89.9%, and 95.6% for southern Germany, and 97.4%, 98.4%, and 99.0% for Latvia regardless of age groups. Conclusions: In both countries, VE after two and three primary doses within-schedule was very high in all age groups. Once receiving booster doses, high VE continued to be observed even in persons with extended intervals since the last dose received, suggesting that longer and more flexible booster intervals may be considered for sustainable long-term protection. (c) 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available